Brokerages Set Immunome, Inc. (NASDAQ:IMNM) PT at $25.00

Immunome, Inc. (NASDAQ:IMNM) has received an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $25.00.

Several equities analysts have recently issued reports on IMNM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Wednesday, October 8th. Stephens lifted their price target on shares of Immunome from $25.00 to $33.00 and gave the stock an “overweight” rating in a research report on Monday, November 17th. Truist Financial assumed coverage on Immunome in a report on Monday, December 1st. They issued a “buy” rating and a $36.00 price target on the stock. Wedbush reissued an “outperform” rating and set a $21.00 price objective on shares of Immunome in a research note on Friday, November 7th. Finally, Guggenheim reaffirmed a “buy” rating and set a $25.00 target price on shares of Immunome in a research report on Monday, August 25th.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently bought and sold shares of IMNM. T. Rowe Price Investment Management Inc. raised its holdings in shares of Immunome by 37.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company’s stock valued at $50,843,000 after acquiring an additional 2,054,640 shares during the period. Redmile Group LLC raised its stake in Immunome by 11.0% during the 1st quarter. Redmile Group LLC now owns 5,361,187 shares of the company’s stock valued at $36,081,000 after purchasing an additional 533,161 shares during the period. Vanguard Group Inc. raised its stake in Immunome by 8.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,893,626 shares of the company’s stock valued at $57,304,000 after purchasing an additional 368,674 shares during the period. EcoR1 Capital LLC lifted its holdings in shares of Immunome by 5.2% in the first quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company’s stock valued at $27,454,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Immunome by 6.7% in the second quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company’s stock worth $17,305,000 after buying an additional 117,523 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Stock Performance

IMNM opened at $19.57 on Thursday. The company has a market capitalization of $1.79 billion, a PE ratio of -6.63 and a beta of 2.17. The stock’s fifty day moving average is $16.94 and its 200-day moving average is $12.27. Immunome has a one year low of $5.15 and a one year high of $20.80.

Immunome (NASDAQ:IMNM) last released its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. On average, equities research analysts forecast that Immunome will post -2.21 EPS for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.